logo
Takeaways from interviews with families forever changed by diseases that vaccines can prevent

Takeaways from interviews with families forever changed by diseases that vaccines can prevent

Associated Press15 hours ago

SIOUX FALLS, S.D. (AP) — In the time before widespread vaccination, devastating infectious diseases ran rampant in America, killing millions of children and leaving others with lifelong health problems.
Over the next century, vaccines virtually wiped out long-feared scourges like polio and measles and drastically reduced the toll of many others. Today, however, some preventable, contagious diseases are making a comeback as vaccine hesitancy pushes immunization rates down. And well-established vaccines are facing suspicion even from public officials, with Robert F. Kennedy Jr., a longtime anti-vaccine activist, running the federal health department.
'This concern, this hesitancy, these questions about vaccines are a consequence of the great success of the vaccines – because they eliminated the diseases,' said Dr. William Schaffner, an infectious disease expert at Vanderbilt University Medical Center. 'If you're not familiar with the disease, you don't respect or even fear it. And therefore you don't value the vaccine.'
Anti-vaccine activists even portray the shots as a threat, focusing on the rare risk of side effects while ignoring the far larger risks posed by the diseases themselves — and years of real-world data that experts say proves the vaccines are safe.
Some Americans know the reality of vaccine-preventable diseases all too well. Here are takeaways from interviews with a few of them by The Associated Press.
Getting a disease while pregnant can change two lives.
Janith Farnham has helped shepherd her daughter Jacque through life for decades. Jacque, 60, was born with congenital rubella syndrome, which resulted in hearing, eye and heart problems at birth. There was no vaccine against rubella back then, and Janith contracted it in early pregnancy.
Though Janith, 80, did all she could to help Jacque thrive, the condition took its toll. Jacque eventually developed diabetes, glaucoma, autistic behaviors and arthritis.
Today, Jacque lives in an adult residential home and gets together with Janith four or five days a week. Janith marvels at Jacque's sense of humor and affectionate nature despite all she's endured. Jacque is generous with kisses and often signs 'double I love yous,' even to new people she meets.
Given what her family has been through, Janith finds it 'more than frustrating' when people choose not to get children the MMR shot against measles, mumps and rubella.
'I know what can happen,' she said. 'I just don't want anybody else to go through this.'
Delaying a vaccine can be deadly.
More than half a century has passed, but Patricia Tobin still vividly recalls seeing her little sister Karen unconscious on the bathroom floor.
It was 1970, Karen was 6, and she had measles. The vaccine against it wasn't required for school in Miami where they lived. Though Karen's doctor discussed immunizing the first grader, their mother didn't share his sense of urgency.
'It's not that she was against it,' Tobin said. 'She just thought there was time.'
Then came a measles outbreak. After she collapsed in the bathroom, Karen never regained consciousness. She died of encephalitis.
'We never did get to speak to her again,' Tobin said.
Today, all states require that children get certain vaccines to attend school. But a growing number of people are making use of exemptions. Vanderbilt's Schaffner said fading memories of measles outbreaks were exacerbated by a fraudulent, retracted study claiming a link between the MMR shot and autism.
The result? Most states are below the 95% vaccination threshold for kindergartners — the level needed to protect communities against measles outbreaks.
Preventable diseases can have long-term effects.
One of Lora Duguay's earliest memories is lying in a hospital isolation ward with her feverish, paralyzed body packed in ice. She was three years old.
It was 1959 and Duguay, of Clearwater, Florida, had polio. It was one of the most feared diseases in the U.S., experts say, causing some terrified parents to keep children inside and avoid crowds during epidemics.
Given polio's visibility, the vaccine against it was widely and enthusiastically welcomed. Given polio's visibility, the vaccine against it was widely and enthusiastically welcomed. But the early vaccine that Duguay got was only about 80% to 90% effective. Not enough people were vaccinated or protected yet to stop the virus from spreading.
Though treatment helped her walk again, she eventually developed post-polio syndrome, a neuromuscular disorder that worsens over time. She now gets around in a wheelchair.
The disease that changed her life twice is no longer a problem in the U.S. So many children get the vaccine — which is far more effective than earlier versions — that it doesn't just protect individuals but it prevents occasional cases that arrive in the U.S. from spreading further and protects the vulnerable.
When people aren't vaccinated, the vulnerable remain at risk.
Every night, Katie Van Tornhout rubs a plaster cast of a tiny foot, a vestige of the daughter she lost to whooping cough at just 37 days old.
Callie Grace was born on Christmas Eve 2009. When she turned a month old, she began having symptoms of pertussis, or whooping cough. She was too young for the Tdap vaccine against it and was exposed to someone who hadn't gotten their booster shot.
At the hospital, Van Tornhout recalled, the medical staff frantically tried to save her, but 'within minutes, she was gone.'
Today, Callie remains part of her family's life, and Van Tornhout shares the story with others as she advocates for vaccination.
'It's up to us as adults to protect our children – like, that's what a parent's job is,' Van Tornhout said. 'I watched my daughter die from something that was preventable … You don't want to walk in my shoes.'
____
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Experts Urge Caution as Study Links This Popular Drink to 2x the Risk of Diabetes
Experts Urge Caution as Study Links This Popular Drink to 2x the Risk of Diabetes

Yahoo

time42 minutes ago

  • Yahoo

Experts Urge Caution as Study Links This Popular Drink to 2x the Risk of Diabetes

Experts Urge Caution as Study Links This Popular Drink to 2x the Risk of Diabetes originally appeared on Parade. There's nothing quite like a crisp diet soda on a hot day. It's cool, bubbly and somehow so refreshing. Add some lime and you've got a summertime treat. You can even make a dirty soda by adding a little cream. Yum! But a new study is shining light on diet soda's health effects, and they might not be as harmless as they seem. A new study has found that consuming artificially sweetened beverages, which are commonly marketed as the 'healthier' alternative to sugary drinks, could significantly increase your risk of developing type 2 diabetes. Researchers collected data on more than 4,654 adults in the 30-year-long Coronary Artery Risk Development in Young Adults (CARDIA) study. They assessed the diets of participants at the start of the study, then again after seven and 20 years. 🎬 SIGN UP for Parade's Daily newsletter to get the latest pop culture news & celebrity interviews delivered right to your inbox 🎬 Researchers discovered that individuals who consumed the highest amounts of artificially sweetened drinks, like diet sodas or sugar-free flavored waters, were more than twice as likely to develop type 2 diabetes than those who rarely drank them. That's a 129% increase in risk, raising serious questions about what we're really sipping on when we go 'sugar-free.'The study adds fuel to the growing debate around artificial sweeteners. Long considered a safer option for those watching their weight or blood sugar, these sugar substitutes may interfere with insulin sensitivity and disrupt gut health, which are two key factors in developing diabetes. While the beverages contain few or no calories, their long-term metabolic effects may not be so benign. Of course, sugary drinks aren't off the hook either. Regular sodas, sweetened teas and energy drinks remain one of the most well-documented contributors to rising diabetes and obesity rates worldwide. Even 100% fruit juices, which many perceive as healthy, can elevate blood sugar when consumed in excess. This new study challenges the widely accepted belief that diet drinks are a safe swap. And while more research is needed to pinpoint exactly how artificial sweeteners may influence insulin response, the evidence so far suggests that moderation—and even reconsideration—is warranted. So, what should you drink instead? Nutrition experts continue to recommend simple, no-frills hydration. Water remains the gold standard, but unsweetened tea and black coffee are also considered safe and beneficial for most people. Infused waters with fruit or herbs can offer a flavorful twist without the potential downsides of sugar or artificial sweeteners. I'm a daily Coke Zero drinker, but after this study, I may be willing to make a change. I do love iced tea!Experts Urge Caution as Study Links This Popular Drink to 2x the Risk of Diabetes first appeared on Parade on Jun 27, 2025 This story was originally reported by Parade on Jun 27, 2025, where it first appeared.

AbbVie's Elahere Market Expected to Skyrocket to $6B by 2034 in Ovarian Cancer Treatment
AbbVie's Elahere Market Expected to Skyrocket to $6B by 2034 in Ovarian Cancer Treatment

Yahoo

time44 minutes ago

  • Yahoo

AbbVie's Elahere Market Expected to Skyrocket to $6B by 2034 in Ovarian Cancer Treatment

AbbVie Inc. (NYSE:ABBV) is one of the undervalued S&P 500 stocks to buy according to hedge funds. On June 25, the 'Elahere Market Opportunities and Strategies to 2034' report was added to offering. It stated that the global market for Elahere, which is a treatment primarily for ovarian cancer, is anticipated to experience rapid growth and is projected to surge from nearly $502.56 million in 2024 to $6.07 billion by 2034 at a CAGR of 28.68% from 2029. AbbVie, through its acquisition of ImmunoGen, is currently the sole and dominant player in the Elahere market, holding a 100% market share in 2023. AbbVie completed its acquisition of ImmunoGen on February 12 in 2024, in a deal that was valued at ~$10.1 billion. The acquisition was made to support AbbVie's oncology pipeline, particularly with Elahere. A pharmacist handing out a pharmaceutical drug to a patient in a drug store or chemist. Elahere is indicated for ovarian neoplasms, which constituted the largest segment by clinical indication and accounted for 85.44% or $429.38 million of the market in 2024. This segment is expected to remain the fastest-growing with a CAGR of 29.67% during the 2024-2029 period. North America was the largest regional market for Elahere in 2024, and accounted for 97.09% of the total, or $487.92 million. AbbVie Inc. (NYSE:ABBV) is a research-based biopharmaceutical company that researches, develops, manufactures, commercializes, and sells medicines and therapies worldwide. While we acknowledge the potential of ABBV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Novo Nordisk (NVO) Terminates Hims & Hers Partnership Over Wegovy Sales Issues
Novo Nordisk (NVO) Terminates Hims & Hers Partnership Over Wegovy Sales Issues

Yahoo

timean hour ago

  • Yahoo

Novo Nordisk (NVO) Terminates Hims & Hers Partnership Over Wegovy Sales Issues

Novo Nordisk A/S (NYSE:NVO) is one of the 12 stocks that will make you rich in 10 years. On June 23, the company discontinued its partnership with Hims & Hers concerning selling its weight-loss drug, Wegovy. This decision was made less than two months after the companies had initially announced their collaboration. A healthcare professional holding a device with innovative technology developed by the medical technology company. According to Novo Nordisk, Hims & Hers failed to adhere to the law prohibiting mass sales of compounded drugs under the 'false guise of 'personalization'.' The company accused its partner of disseminating 'deceptive marketing' that risks patient safety and selling 'illegitimate, knockoff versions' of Wegovy. Novo Nordisk states that its investigation showed the active pharmaceutical ingredients (APIs) in these knockoff drugs, particularly 'semaglutide' from telehealth entities and compounding pharmacies, are manufactured by foreign suppliers in China and were often not inspected by the FDA. In response, Andrew Dudum, CEO of Hims & Hers, stated on X that the company is 'disappointed to see Novo Nordisk management misleading the public.' Dudum alleged that Novo Nordisk's commercial team 'increasingly pressured us to control clinical standards and steer patients to Wegovy regardless of whether it was clinically best for patients.' He asserted that Hims & Hers 'refuse[s] to be strong-armed by any pharmaceutical company's anticompetitive demands that infringe on the independent decision-making of providers and limit patient choice.' Novo Nordisk A/S (NYSE: NVO) is a Danish healthcare company operating globally. It develops, manufactures, and markets pharmaceutical products for the treatment of chronic diseases, primarily diabetes and obesity. Its well-known products include Ozempic, Wegovy, Rybelsus, and Norditropin. While we acknowledge the potential of NVO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store